8-K: Precision BioSciences Reports Strong Q2 2024 Results and Advances Gene Editing Programs

Precision BioSciences announced positive second quarter 2024 financial results, highlighted by a significant increase in revenue and progress in its gene editing programs, including a strengthened cash position.

Summary

• Precision BioSciences reported a net income of $32.7 million for the second quarter of 2024, a significant turnaround from a net loss of $11.9 million in the same period of 2023.
• The company's revenue increased to $49.9 million, up from $19.8 million in the second quarter of 2023, primarily due to the recognition of deferred revenue from the termination of the Prevail Therapeutics agreement.
• Research and development expenses rose to $17.2 million, compared to $13.1 million in the prior year, driven by the advancement of the PBGENE-HBV and PBGENE-PMM programs.
• General and administrative expenses decreased to $8.5 million from $9.8 million in the same quarter of the previous year, due to reduced employee and share-based compensation costs.
• Precision BioSciences had approximately $123.6 million in cash and cash equivalents as of June 30, 2024, with an expected cash runway into the second half of 2026.
• The company is advancing its wholly owned programs, PBGENE-HBV for chronic Hepatitis B and PBGENE-PMM for m.3243 mitochondrial disease, with IND and/or CTA submissions planned for 2024 and 2025, respectively.
• Precision regained control of three advanced preclinical programs, including a novel gene editing approach for Duchenne Muscular Dystrophy, and is assessing their future development.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong financial results, significant progress in key programs, and a solid cash runway. The company's strategic moves and advancements in its technology suggest a promising future.

Positives

• The company achieved a significant increase in revenue, primarily due to the termination of the Prevail Therapeutics agreement.
• Precision BioSciences has a strong cash position, with an expected runway into the second half of 2026.
• The company is making substantial progress in advancing its wholly owned gene editing programs, PBGENE-HBV and PBGENE-PMM.
• The addition of experienced clinical investigators to the Hepatitis Scientific Advisory Board enhances the company's expertise.
• The company has regained control of three advanced preclinical programs, providing new opportunities for development.
• The company has secured a term loan of $22.5 million, strengthening its financial position.

Negatives

• Research and development expenses increased by $4.1 million compared to the same period last year, due to the advancement of the PBGENE-HBV and PBGENE-PMM programs.
• The company's net income includes a $7.8 million non-cash gain on the fair value of warrant liability, which does not impact the cash runway.

Risks

• The company's success is dependent on the progression and success of its programs and product candidates.
• There are risks associated with the company's ability to procure sufficient funding to advance its programs.
• The company faces competition in the genome editing, biopharmaceutical, and biotechnology fields.
• There are potential manufacturing problems associated with the development or commercialization of any of the company's product candidates.
• The company's success is dependent on its ability to obtain and maintain intellectual property protection for its technology and product candidates.

Future Outlook

The company expects to submit an IND and/or CTA for PBGENE-HBV in 2024 and for PBGENE-PMM in 2025. They anticipate a cash runway into the second half of 2026 and plan to provide updates on their programs and partnerships.

Management Comments

• Michael Amoroso, President and CEO, stated that the company has made excellent progress against key priorities in the first half of 2024.
• Mr. Amoroso emphasized that the company is sufficiently capitalized to propel its two wholly owned programs to Phase 1 data readouts in 2025 and 2026.

Industry Context

This announcement highlights Precision BioSciences' progress in the competitive gene editing space, particularly in in vivo therapies. The company's focus on its proprietary ARCUS platform and its application to various diseases positions it as a key player in the field. The regained control of three programs from Prevail Therapeutics also indicates a strategic shift towards internal development and potential new partnerships.

Comparison to Industry Standards

• Precision's ARCUS platform is differentiated from CRISPR/Cas, base editors, and prime editors due to its single-component nucleases that do not require a guide RNA, allowing it to penetrate mitochondrial membranes, a key advantage in mitochondrial disease treatment.
• The company's reported 40% to 45% high efficiency and durable gene insertion in non-dividing cells in adult nonhuman primates is a significant achievement, as most gene editing technologies struggle with non-dividing cells.
• The company's in vivo approach for sickle cell anemia and beta thalassemia, in collaboration with Novartis, is unique compared to ex vivo approaches, potentially overcoming disparities in patient treatment access.
• The company's focus on in vivo gene editing for diseases like Hepatitis B and mitochondrial diseases is in line with the industry's trend towards more direct and efficient therapeutic approaches.

Related Party Transactions

• Members of the senior leadership team purchased 25,000 shares of common stock at a price of $12.00 per share for an aggregate amount of $300,000.

Stakeholder Impact

• Shareholders will likely view the positive financial results and program advancements favorably.
• Employees may benefit from the company's growth and success.
• Patients with chronic Hepatitis B, m.3243 mitochondrial disease, and Duchenne Muscular Dystrophy may benefit from the company's gene editing therapies.
• Partners and collaborators may see increased opportunities for collaboration and development.

Next Steps

• Precision BioSciences plans to submit an IND and/or CTA for PBGENE-HBV in 2024.
• The company anticipates filing an IND and/or CTA for PBGENE-PMM in 2025.
• Precision will conduct a portfolio assessment for the three regained programs and provide an update on their development plans.
• The company expects initial data from the iECURE-OTC trial in late 2024 or 2025.
• Precision plans to provide an additional program update for PBGENE-HBV later this year.

Key Dates

Keywords

gene editing, ARCUS, in vivo, Hepatitis B, mitochondrial disease, Duchenne Muscular Dystrophy, clinical trials, IND, CTA, biotechnology, PBGENE-HBV, PBGENE-PMM, financial results